GMP IPO Watch
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund
Regular Plan · Growth · Edelweiss Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.74% | +3.19% | 145 of 283 |
| 1M | +4.74% | +2.85% | 69 of 283 |
| 3M | +2.91% | -2.37% | 2 of 283 |
| 6M | +16.71% | +1.56% | 2 of 278 |
| YTD | +17.52% | -0.86% | 4 of 283 |
| 1Y | +20.22% | -0.15% | 2 of 263 |
| 2Y | +11.26% | +2.58% | 5 of 193 |
| 3Y | +20.84% | +9.71% | 4 of 142 |
| 5Y | +14.28% | +8.49% | 3 of 47 |
| INCEPTION | +16.09% | — | — |
Ranked among: Other Scheme - Index Funds.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +3.78% | +20.84% | -11.85% | 69% | 28% |
| 6M | +7.51% | +25.88% | -13.10% | 74% | 31% |
| 1Y | +14.32% | +48.96% | -10.89% | 79% | 35% |
| 2Y | +15.05% | +32.12% | +0.75% | 100% | 44% |
| 3Y | +16.90% | +23.06% | +10.37% | 100% | 46% |
| 5Y | +13.36% | +15.43% | +11.67% | 100% | 45% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity99.91%
- Debt0.00%
- Cash0.09%
- Other0.00%
Market Cap Split
- Large Cap31.51%
- Mid Cap34.40%
- Small Cap2.69%
- Others31.40%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 37.48 | 23.32 |
| P/B | 5.98 | 3.82 |
| Price / Sales | 5.93 | 3.28 |
| Price / Cash Flow | 27.29 | 17.26 |
| Dividend Yield (%) | 0.97 | 1.64 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 10.45% | -0.54% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 7.09% | +0.13% |
| ELI LILLY & CO | Pharmaceuticals | 6.46% | +0.12% |
| Apollo Hospitals | Equity | 5.25% | -0.26% |
| JOHNSON & JOHNSON | Pharmaceuticals | 4.45% | +0.08% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 4.44% | +0.30% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 4.38% | -0.07% |
| Cipla | Pharmaceuticals & Biotechnology | 4.34% | -0.04% |
| Max Healthcare Institute | Equity | 4.19% | -0.33% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 3.95% | +0.39% |
| ABBVIE INC | Biotechnology | 3.22% | +0.12% |
| Lupin | Pharmaceuticals & Biotechnology | 2.97% | -0.11% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 2.77% | +0.01% |
| MERCK & CO.INC | Pharmaceuticals | 2.50% | +0.01% |
| Fortis Healthcare | Equity | 2.41% | -0.33% |
View all 48 holdings
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 2.11% | -0.04% |
| NOVARTIS AG | Pharmaceuticals | 1.82% | -0.08% |
| THERMO FISHER SCIENTIFIC INC | Life Sciences Tools & Services | 1.75% | +0.18% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 1.72% | +0.02% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 1.65% | +0.11% |
| AMGEN INC | Biotechnology | 1.59% | +0.01% |
| Biocon | Pharmaceuticals & Biotechnology | 1.47% | -0.17% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 1.38% | +0.01% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 1.37% | +0.05% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 1.37% | +0.04% |
| GILEAD SCIENCES INC | Biotechnology | 1.29% | +0.05% |
| ABBOTT LABORATORIES | Equity | 1.20% | -0.11% |
| Aster DM Quality Care | Equity | 1.04% | -0.04% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 1.01% | +0.04% |
| INTUITIVE SURGICAL INC | Equity | 1.00% | +0.09% |
| DANAHER CORP | Equity | 0.98% | +0.05% |
| VERTEX PHARMACEUTICALS INC | Biotechnology | 0.93% | -0.02% |
| Novo Nordisk A/S | Pharmaceuticals & Biotechnology | 0.85% | -0.15% |
| MEDTRONIC PLC | Equity | 0.77% | -0.02% |
| Global Health | Equity | 0.70% | -0.03% |
| Narayana Hrudayalaya | Equity | 0.70% | -0.01% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 0.67% | -0.05% |
| STRYKER CORP | Equity | 0.66% | -0.10% |
| Wockhardt | Pharmaceuticals & Biotechnology | 0.62% | — |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 0.55% | +0.07% |
| Regeneron Pharmaceuticals Inc | Pharmaceuticals | 0.55% | -0.02% |
| BECTON DICKINSON AND CO | Equity | 0.34% | -0.03% |
| AGILENT TECHNOLOGIES INC | Life Sciences Tools & Services | 0.34% | +0.04% |
| IQVIA HOLDINGS INC | Life Sciences Tools & Services | 0.31% | +0.01% |
| WATERS CORP | Pharmaceuticals | 0.30% | +0.02% |
| Clearing Corporation of India Ltd. | Net Current Assets | 0.10% | — |
| Accrued Interest | Net Current Assets | 0.00% | — |
| Net Receivables/(Payables) | Net Current Assets | -0.01% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 11.59 | 12.38 | Low Volatility |
| 3Y | 11.78 | 10.25 | High Volatility |
| 5Y | 11.83 | 13.82 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.17 | -0.51 | Above Average |
| 3Y | 1.25 | 0.26 | Above Average |
| 5Y | 0.70 | 0.19 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 2.65 | 12.56 | Below Average |
| 3Y | 2.58 | 8.16 | Below Average |
| 5Y | 1.85 | 1.31 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Tracking Difference
Versus MSCI India Domestic & World Healthcare 45 Index, as of Sep 2026.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
ICICI Prudential Nifty Pharma Index Fund
Direct Plan · IDCW
|
+22.53% | +22.50% | — | +21.44% |
|
Tata Nifty Capital Markets Index Fund
Direct Plan · Growth Option
|
+19.89% | — | — | +21.71% |
|
Motilal Oswal Nifty Capital Market Index Fund
Regular Plan · Growth
|
+19.31% | — | — | +16.06% |
|
Motilal Oswal S&P 500 Index Fund
Direct Plan · GROWTH
|
+18.19% | +25.74% | +16.20% | +20.46% |
|
Tata Nifty MidSmall Healthcare Index Fund
Regular Plan · IDCW Payout Option
|
+17.24% | — | — | +17.73% |
|
Motilal Oswal Nifty MidSmall Healthcare Index Fund
Regular Plan · Growth
|
+17.19% | — | — | +11.55% |
|
ICICI Prudential NASDAQ 100 Index Fund
Regular Plan · Growth
|
+15.21% | +27.99% | +16.74% | +17.49% |
|
Bandhan BSE Healthcare Index Fund
Regular Plan · Growth
|
+13.22% | — | — | +7.26% |
|
Motilal Oswal Nifty India Defence Index Fund
Regular Plan · Growth
|
+13.06% | — | — | +4.19% |
|
DSP Nifty Healthcare Index Fund
Regular Plan · Growth
|
+12.65% | — | — | +12.61% |
More From Edelweiss Asset Management Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Edelweiss US Value Equity Offshore Fund
Direct Plan · Growth
|
+29.74% | +21.68% | +14.03% | +13.46% |
| Edelweiss Silver ETF | +26.32% | — | — | +35.41% |
|
Edelweiss Gold and Silver ETF FOF
Direct Plan · Growth
|
+23.25% | +34.17% | — | +30.69% |
|
Edelweiss Emerging Markets Opportunities Equity Offshore Fund
Direct Plan · Growth
|
+22.43% | +25.06% | +9.43% | +11.36% |
|
Edelweiss Recently Listed IPO Fund
Direct Plan · Growth
|
+20.01% | +17.71% | +10.98% | +15.60% |
| Edelweiss Gold ETF | +16.79% | — | — | +31.46% |
|
Edelweiss Europe Dynamic Equity Offshore Fund
Direct Plan · Growth
|
+16.72% | +25.29% | +14.57% | +13.15% |
|
Edelweiss ASEAN Equity Off-shore Fund
Direct Plan · Growth
|
+6.68% | +14.36% | +7.41% | +8.53% |
|
Edelweiss Equity Savings Fund
Direct Plan · Growth
|
+6.67% | +11.23% | +9.52% | +10.47% |
|
Edelweiss Arbitrage Fund
Direct Plan · Growth
|
+6.59% | +7.36% | +6.92% | +6.84% |
About This Scheme
Investment Objective
The Scheme will invest in stocks comprising of the MSCI India Domestic IMI and World Healthcare Select Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors. However, there is no assurance that the investment objective of the Scheme will be realized and the Scheme does not assure or guarantee any returns.
Stated Asset Allocation
1. Stocks comprising the MSCI India Domestic IMI and World Healthcare Select Index - 95-100% 2. Debt and Money Market Instruments/ units of Liquid Mutual Fund - 0-5%
Exit Load
Nil
Fund Managers
Mr. Bhavesh Jain;Ms. Manasi Jalgaonkar; Mr. Amit Vora (for investments in foreign securities)
Co-Manage, Ms. Manasi Jalgaonkar - Assistant Fund Manager
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.